Compare COGT & GTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | GTX |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.2B |
| IPO Year | 2018 | 2021 |
| Metric | COGT | GTX |
|---|---|---|
| Price | $31.65 | $26.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $36.21 | $20.40 |
| AVG Volume (30 Days) | 1.5M | ★ 2.6M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.56% |
| EPS Growth | N/A | ★ 20.63 |
| EPS | N/A | ★ 0.49 |
| Revenue | $7,871,000.00 | ★ $3,584,000,000.00 |
| Revenue This Year | N/A | $4.16 |
| Revenue Next Year | $1,733.58 | $3.27 |
| P/E Ratio | ★ N/A | $53.59 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $11.61 | $12.26 |
| 52 Week High | $43.73 | $36.25 |
| Indicator | COGT | GTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.56 | 40.29 |
| Support Level | $30.90 | $25.67 |
| Resistance Level | $37.69 | $28.38 |
| Average True Range (ATR) | 1.25 | 0.76 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 9.59 | 26.78 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.